鈥檚 reported net income stood at $3.11bn in the first quarter (Q1) of 2024, marking a decrease of 44% from $5.54bn posted in Q1 2023.
The pharmaceutical giant鈥檚 reported diluted earnings per share (EPS) fell by 44% to $0.55 in Q1 2024 from $0.97 in Q1 2023.
The company’s revenues for the quarter totalled $14.87bn, a 20% decrease from $18.48bn in the previous year’s corresponding quarter, with a year-on-year operational decline of $3.5bn (19%). This was due to a substantial drop in global revenues from the Covid-19 therapies, Comirnaty and Paxlovid.
Foreign exchange rates also negatively impacted revenues by $107m (1%).
Excluding the contributions from Covid-19 treatments, Pfizer’s revenues stood at $12.5bn, an operational increase of 11% or $1.2bn compared to the same quarter of the previous year.
Pfizer chairman and CEO Dr Albert Bourla stated: 鈥淲e delivered strong performance in our non-Covid product portfolio in the first quarter of 2024, including increased revenue from several of our recent commercial launches and acquired products, as well as robust year-on-year growth for several key in-line brands, namely the Vyndaqel family, Eliquis and the Prevnar family.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData鈥淚n addition, we had strong oncology revenue contributions from Ibrance, Xtandi, Padcev and Adcetris. Our Paxlovid revenues in the quarter indicate a successful transition into the commercial marketplace in the US and a demonstrated trust in the brand.鈥�
Pfizer has raised its adjusted diluted EPS guidance for the full year 2024 to between $2.15 and $2.35 from a previous range of between $2.05 and $2.25.
The company continues to project full-year 2024 revenues between $58.5bn and $61.5bn.
This forecast includes $8bn joint anticipated revenues from Comirnaty ($5bn) and Paxlovid ($3bn).
Last month, the company obtained US Food and Drug Administration approval for its one-time gene therapy BEQVEZ (fidanacogene elaparvovec-dzkt) to treat adults with moderate to severe haemophilia B.
